United Therapeutics wins FDA nod for rare cancer med; Lundbeck's Brintellix set for cognitive-improvement claim; Pfizer consolidates OTC media planning;

> The FDA approved United Therapeutics' ($UTHR) new drug Unituxin for a rare form of pediatric cancer, neuroblastoma; some 650 new cases are diagnosed in the U.S. each year. Report

> Lundbeck's antidepressant Brintellix is set to become the first EU-approved antidepressant cited for its ability to improve cognitive function, thanks to a label update backed by the Committee for Medicinal Products for Human Use. Report

> Pfizer ($PFE) has consolidated its media planning for over-the-counter brands such as Advil and Chapstick, moving them to Carat, Mediapost says. Report

> China fined Procter & Gamble's ($PG) Crest brand for nearly $1 million for alleged false advertising, saying the U.S. brand touched up images to make teeth look whiter. Report

> Kythera Biopharmaceuticals ($KYTH) won an FDA panel's recommendation for its new "double chin" remedy, ATX-101, and the agency is expected to hand down its decision by May 13. Report

> Australia's competition watchdog is taking Reckitt Benckiser to court over the "specific pain" claims on its range of Nurofen products, which all contain the same active ingredients. Report

> Bayer teamed up with the New Jersey Devils hockey team for "Bayer Fights Cancer Night" at two home games this season. Release

> Ethics and compliance managers in the pharma industry are focusing on company values in their training programs, with less emphasis on specific training on complying with FDA and Justice Department regulations. Release

And Finally... A match made somewhere: Mr. Mucus and Myrbetrig's talking bladder. Report

Suggested Articles

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.